TNYATenaya Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Tenaya Therapeutics, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TNYAThis | $152M#9 | — | 2.2x#6 | — | — | 18.5%#5 | — | -130.5%#10 | — | — | -44.6%#12 | — |
| VYGR | $186M#3 | — | 1.2x#4 | 4.6x#3 | -49.5%#4 | -84.2%#12 | -326.6%#3 | -77.6%#8 | — | — | -29.2%#8 | — |
| CHRS | $193M#2 | — | 3.2x#8 | 4.6x#2 | 59.8%#1 | 489.4%#1 | -429.5%#4 | 276.2%#3 | -351.2%#2 | — | -7.7%#5 | — |
| ABOS | $186M#4 | — | 3.3x#10 | — | — | -18.6%#10 | — | -211.9%#13 | -421.4%#3 | — | 104.4%#2 | — |
| DTIL | $178M#5 | — | 3.9x#12 | 5.2x#4 | -50.1%#5 | -738.0%#14 | -152.2%#2 | -101.0%#9 | — | — | 41.2%#4 | — |
| OTLK | $167M#6 | — | — | 118.0x#8 | — | 17.2%#6 | -4744.3%#7 | — | -12.8%#1 | — | -33.5%#9 | — |
| HUMA | $158M#7 | — | 5.1x#13 | 77.6x#7 | — | 72.5%#3 | -5306.0%#8 | -130.6%#11 | — | — | -62.8%#14 | — |
| ARMP | $155M#8 | — | — | — | — | -818.8%#15 | — | — | — | — | 41.5%#3 | 0.1%#1 |
| NMRA | $145M#10 | — | 3.2x#9 | — | — | -2.8%#9 | — | 532.2%#2 | -594.0%#4 | — | -46.2%#13 | — |
| CRBU | $140M#11 | — | 1.4x#5 | 12.6x#6 | 11.7%#2 | 0.7%#7 | -1329.4%#6 | -151.0%#12 | — | — | -24.1%#6 | — |
| LENZ | $128M#12 | — | 0.6x#2 | 6.7x#5 | — | -65.0%#11 | -477.5%#5 | -37.5%#5 | — | — | -90.4%#16 | — |
| ENGN | $127M#13 | 0.8x#1 | 0.6x#1 | — | — | -112.7%#13 | — | -50.9%#6 | — | — | -69.6%#15 | — |
| BDTX | $112M#14 | — | 1.2x#3 | 1.6x#1 | — | 132.1%#2 | 17.9%#1 | 23276.9%#1 | — | — | -38.4%#11 | — |
| ATTO | $1.1B#1 | — | — | — | — | — | — | — | — | — | 333.9%#1 | — |
| CGTX | $101M#15 | — | 3.1x#7 | — | — | 30.9%#4 | — | -71.1%#7 | — | — | -27.3%#7 | — |
| CRDF | $101M#16 | — | 3.8x#11 | 170.5x#9 | -13.2%#3 | -0.9%#8 | -8256.3%#9 | -0.2%#4 | — | — | -35.3%#10 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice